Farringdon Capital Ltd. Buys New Holdings in Integer Holdings Co. (NYSE:ITGR)

Farringdon Capital Ltd. purchased a new position in shares of Integer Holdings Co. (NYSE:ITGR) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 2,871 shares of the medical equipment provider’s stock, valued at approximately $380,000.

A number of other large investors also recently modified their holdings of ITGR. Jump Financial LLC acquired a new position in shares of Integer during the 4th quarter worth about $354,000. Summit Investment Advisors Inc. boosted its holdings in shares of Integer by 5.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,488 shares of the medical equipment provider’s stock valued at $462,000 after buying an additional 175 shares in the last quarter. Townsquare Capital LLC boosted its holdings in shares of Integer by 16.3% in the 4th quarter. Townsquare Capital LLC now owns 31,467 shares of the medical equipment provider’s stock valued at $4,170,000 after buying an additional 4,412 shares in the last quarter. Sterling Capital Management LLC grew its position in shares of Integer by 472.9% in the 4th quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 279 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Integer during the 4th quarter worth $38,073,000. 99.29% of the stock is owned by hedge funds and other institutional investors.

Integer Price Performance

Shares of ITGR opened at $116.99 on Friday. The firm has a market capitalization of $4.08 billion, a PE ratio of 34.82, a P/E/G ratio of 1.72 and a beta of 1.09. The stock’s 50 day moving average is $122.00 and its two-hundred day moving average is $130.61. Integer Holdings Co. has a twelve month low of $104.93 and a twelve month high of $146.36. The company has a current ratio of 2.95, a quick ratio of 2.09 and a debt-to-equity ratio of 0.62.

Integer (NYSE:ITGR) last released its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). Integer had a net margin of 6.92% and a return on equity of 11.65%. The business had revenue of $449.50 million during the quarter, compared to analyst estimates of $446.28 million. Research analysts anticipate that Integer Holdings Co. will post 6.01 earnings per share for the current year.

Analysts Set New Price Targets

ITGR has been the topic of several research reports. KeyCorp raised their price objective on Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Oppenheimer lowered Integer from an “outperform” rating to a “market perform” rating in a research report on Friday, February 21st. Truist Financial decreased their price objective on Integer from $163.00 to $140.00 and set a “buy” rating for the company in a report on Friday, April 11th. Raymond James started coverage on shares of Integer in a report on Friday, March 28th. They issued an “outperform” rating and a $145.00 target price on the stock. Finally, Benchmark increased their price target on shares of Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $146.00.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.